Aligos therapeutics presents nonclinical data for its covid-19 therapeutic in development at the 2021 conference on retroviruses and opportunistic infections

South san francisco, calif., march 08, 2021 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its sars-cov-2 3clpro inhibitor candidate, alg-097111, at the 28th conference on retroviruses and opportunistic infections, being held virtually march 6 to march 10, 2021, during the meeting's science spotlight sessions on saturday, march 6. aligos performed all research in collaboration with belgian university ku leuven, in particular its centre for drug design and discovery (cd3), and the rega institute for medical research.
ALGS Ratings Summary
ALGS Quant Ranking